Genprex (NASDAQ:GNPX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($13.00) by $11.85, FiscalAI reports.
Genprex Stock Performance
NASDAQ:GNPX traded down $0.05 on Monday, reaching $1.77. The company’s stock had a trading volume of 272,789 shares, compared to its average volume of 1,044,523. Genprex has a 1-year low of $1.71 and a 1-year high of $55.00. The firm has a market cap of $5.53 million, a PE ratio of -0.07 and a beta of -0.77. The business’s 50-day moving average price is $2.15 and its two-hundred day moving average price is $4.98.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Hedge Funds Weigh In On Genprex
A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP lifted its holdings in Genprex (NASDAQ:GNPX – Free Report) by 11.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.05% of the company’s stock.
About Genprex
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
See Also
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
